Moderna says FDA requiring more time to review its vaccine for 12- to 17-year-olds
Moderna announced Sunday that the U.S. Food and Drug Administration is requiring additional time to review its adolescent COVID-19 vaccine for 12- to 17-year-olds.
The FDA expects to have the review done by January 2022.
Moderna is authorized in the U.S. for people 18 and older. The company has asked for authorization for 12- to 17-year-olds at the same dose as adults, which is 100 micrograms.
The Pfizer vaccine is currently available to anyone 12 years and old and could be available soon for 5- to 11-year-olds after it gets official Centers for Disease Control and Prevention recommendations.
-ABC News Eric Strauss